Continuing Education Activity

Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist and exhibits minimal to no beta-adrenergic activity. Consequently, the medication is an optimal choice for raising mean arterial pressure by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac myocytes. The US Food and Drug Administration (FDA) has approved intravenous phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. Phenylephrine HCL is also an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels. Furthermore, this medication is administered intranasally to treat uncomplicated nasal congestion and is an OTC additive to topical hemorrhoid medications.

This activity provides a comprehensive overview of the indications, mechanism of action, administration methods, adverse event profile, contraindications, monitoring, and toxicity of phenylephrine relevant to the interprofessional healthcare team to effectively guide patient therapy in the treatment of diverse conditions for which phenylephrine is indicated. 

Objectives:

• Identify the clinical uses of phenylephrine for the treatment of hypotension caused by vasodilation, such as in septic shock and anesthesia.
• Assess patient responses to phenylephrine therapy and monitor hemodynamic parameters and adverse events to ensure optimal outcomes and early recognition of complications.
• Screen patients for contraindications and potential interactions with phenylephrine, particularly in hypersensitivity, bradycardia, severe cardiac dysfunction, and hypovolemia.
• Collaborate with the interprofessional healthcare team and communicate clearly with pharmacists and nurses to ensure accurate dosing and administration of phenylephrine, thereby improving outcomes and enhancing patient safety.

Indications

FDA-Approved Indications

The US Food and Drug Administration (FDA) has approved intravenous (IV) phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. In addition, phenylephrine HCL serves as an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels. Furthermore, this medication is administered intranasally to treat uncomplicated nasal congestion and is an OTC additive to topical hemorrhoid medications.[1][2] 

Off-Label Uses

Phenylephrine is infrequently utilized off-label as an adjunct to neuraxial or peripheral nerve blockade to treat priapism and other conditions, where the intended outcome is localized vasoconstriction and reduced blood flow. 

In IV administration, phenylephrine is frequently used as an anesthetic vasopressor for patients exhibiting normal cardiac function and experiencing hypotension due to the vasodilatory effect of anesthetic medications or non-cardiac shock states. The American Urological Association (AUA) endorses using intracavernosal phenylephrine to treat acute ischemic priapism.[3]

The FDA has recently stated that utilizing phenylephrine as an oral decongestant is ineffective, even at the standard dosage of 10 mg every 4 hours and at higher doses. Notably, this ruling pertains exclusively to oral formulations and does not encompass nasal phenylephrine or other topical phenylephrine preparations.[4] [FDA Clarifies Results. 9.14.23]

Introduction

Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist, exhibiting minimal to no beta-adrenergic activity. Consequently, the medication is an optimal choice for raising mean arterial pressure (MAP) by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac myocytes.[5] Hypotension occurring during general and neuraxial anesthesia continues to be a frequently encountered challenge for anesthesia providers, necessitating swift intervention to avoid prolonged periods of inadequate perfusion.[6]

A patient's blood pressure may fluctuate significantly throughout a surgical procedure due to various factors, including their underlying medical conditions, the dosage of anesthetic medications, volume status, the degree of surgical stimulation, and concurrent use of other blood pressure–modifying medications. Vasopressor medications, such as phenylephrine, are an excellent option for treating patients with hypotension due to their short onset, brief duration of action, and predictable dose-dependent responses.

Phenylephrine has emerged as the preferred vasopressor for its effectiveness in counteracting the frequently observed hypotension associated with spinal anesthetics (60% to 70%) in obstetric patients.[6] Phenylephrine is also used in the intensive care unit (ICU) environment to treat septic and neurogenic shock. With the advent of the Surviving Sepsis Campaign, the management of sepsis has undergone increased scrutiny, leading to the development of a more standardized approach for septic shock states. Norepinephrine is now the preferred vasopressor and inotrope in this context.

 Although phenylephrine is not the preferred initial treatment for septic shock, it is an acceptable medication in cases of norepinephrine-associated arrhythmias, known high cardiac output with hypotension, and as a salvage therapy when used in combination with inotropic and vasopressor medications, especially when low-dose vasopressin has failed to attain the target MAP.[7] Neurogenic shock resulting from acute traumatic spinal cord injury can also lead to a systemic vasodilatory state, frequently observed alongside preserved cardiac output. In such cases, managing these injuries often necessitates the maintenance of higher target MAPs of typically 85 to 90 mm Hg to maintain spinal cord perfusion and reduce secondary injury. Consequently, phenylephrine emerges as a prudent and safe option for maintaining hemodynamic stability in these patients.[8] 

Mechanism of Action

Phenylephrine is a direct-acting sympathomimetic amine that functions as an alpha-1 adrenergic agonist. The drug's chemical structure is closely related to epinephrine and ephedrine, and it exhibits robust vasoconstrictive capabilities when administered via the IV route or applied directly to mucosal membranes. The overall effect of IV phenylephrine on cardiac output and end-organ perfusion is likely to be more complex and variable based on the dosing method—bolus versus infusion, volume status, baseline heart rate, autonomic tone, and underlying cardiac conditions. These variations are attributable to the degree of vasoconstriction, which may result in a temporary increase in preload, arterial constriction leading to heightened systemic vascular resistance and afterload, and reflex bradycardia. These factors collectively contribute to a mixed effect on cardiac output, which can vary depending on the specific patient population.[9][10][11] Phenylephrine binds to alpha-1 receptors that innervate the iris dilator muscle, yielding smooth muscle contraction and subsequent pupil dilation during ophthalmic administration. This dilation can aid in fundoscopic exams, improve exposure during specific surgeries, and facilitate the treatment of various medical conditions.[12]

Pharmacokinetics

Absorption: Phenylephrine's absorption profile differs depending on its route of administration. The ophthalmic application of the medication allows for rapid absorption through the conjunctiva and cornea, resulting in a quick onset of action within minutes. IV administration ensures immediate and complete bioavailability, allowing for rapid systemic distribution. Although rectal administration of the medication is somewhat slower than nasal and IV routes, it results in mucosal absorption, with peak concentration typically achieved in approximately 30 to 60 minutes. Nasal delivery facilitates rapid mucosal absorption, achieving peak plasma concentrations within 15 to 30 minutes.[13]

Distribution: After absorption, phenylephrine effectively penetrates vascular-rich tissues due to its lipophilic nature, enabling central and peripheral effects. Ophthalmic formulations restrict distribution primarily to ocular compartments, resulting in pupil dilation without significant systemic impact. The steady-state volume of distribution of 340 L surpasses the body's total volume, indicating a substantial volume of distribution.

Metabolism: The primary metabolic pathways for phenylephrine include sulfate conjugation, primarily occurring in the intestinal wall, and oxidative deamination catalyzed by monoamine oxidase (MAO)-A and MAO-B enzymes. Glucuronidation also serves as an additional metabolic route for phenylephrine.[13]

Elimination: Renal excretion is the primary elimination pathway for phenylephrine, with most of the drug excreted unchanged in the urine, regardless of whether it was administered nasally, ophthalmically, or rectally. To maintain therapeutic effectiveness, the short half-life of phenylephrine, which is approximately 2.5 to 3 hours, requires frequent dosing intervals, especially when administered via the IV route.

Administration

Dosage Forms

The most common routes of phenylephrine administration include topical, IV, intranasal, ophthalmic, and rectal. Oral formulations should be avoided due to their lack of efficacy.

Although less common, phenylephrine has been used as an adjunct to peripheral nerve blockade in the epidural space, intracavernously, via intramuscular injection, and subcutaneously.[14][15] When administering phenylephrine via the IV route, the usual dosing range is 50 to 100 mcg in aliquots. The drug often necessitates repeated dosing due to its rapid onset of action—1 to 3 minutes—and relatively short duration of effect—5 to 20 minutes.[16] 

Adult Dosage 

Phenylephrine can be administered to patients through weight-based or non-weight–based infusions. Dosages usually range from 0.1 to 1.5 mcg/kg/min.[17] Contrary to the conventional teaching that all vasoactive drugs should be administered through central venous access to prevent tissue necrosis in case of extravasation, phenylephrine has proven safe and efficacious when administered via peripheral IV catheters. This is achievable through proper dilution, appropriate vein and catheter selection, and frequent site inspection.[18] 

 Strengths

Ophthalmic solutions of phenylephrine offer a diverse array of concentrations and additives tailored to achieve specific effects. Medical practitioners commonly use these concentrations that are available in strengths of 1%, 2.5%, or 10%. The 1% formulations are frequently combined with 0.2% cyclopentolate for dilated fundus and cycloplegic examinations in newborns younger than 3 months. The 2.5% formulations are the preferred choice for dilated fundus examinations in adults and children older than 3 months and as an aid for diagnosing episcleritis. Although the 10% formulation is less frequently used primarily due to concerns regarding systemic absorption, it may be used for dilated examinations and to provide exposure during surgical procedures.

OTC phenylephrine combination drops can be found in concentrations as low as 0.12% and are often marketed for red-eye relief or the treatment of uncomplicated conjunctivitis. In addition, phenylephrine is available as an FDA-approved nasal solution, typically ranging from 0.125% to 1%.[19][20]

Specific Patient Populations

Hepatic impairment: In cases of liver impairment, caution is warranted when dosing phenylephrine, as the liver plays a pivotal role in synthesizing essential factors contributing to blood pressure regulation. These include clotting factors, angiotensinogen, nitric oxide, and vasoactive substances. Alterations in drug metabolism and reduced clearance in cases of hepatic impairment may necessitate dosage adjustments. To ensure the safe and effective use of phenylephrine in individuals with liver impairment, it is often necessary to implement individualized dosing, which may involve larger than standard doses, along with vigilant monitoring.

Renal impairment: Patients with end-stage renal disease undergoing hemodialysis tend to exhibit heightened sensitivity to phenylephrine, as dose-response data indicates. Therefore, it is advisable to consider administering lower doses of IV phenylephrine in patients with renal impairment.

Pregnancy considerations: According to the American Society of Anesthesiology guidelines, IV ephedrine and phenylephrine are suitable options for managing hypotension resulting from neuraxial anesthesia during pregnancy. In cases where maternal bradycardia is not a concern, phenylephrine may be preferred due to its potential to improve fetal acid-base balance in uncomplicated pregnancies.[21]

Breastfeeding considerations: The systemic administration of phenylephrine may potentially reduce milk production. Due to the absence of breastfeeding safety data for oral phenylephrine, it is prudent to explore alternative options, particularly when nursing a newborn or preterm infant. Using phenylephrine through nasal spray or ophthalmic drops is less likely to have a negative impact on lactation for breastfeeding individuals. To minimize the drug's effects after eye drop application, it is advisable to apply pressure near the tear duct for at least 1 minute and subsequently remove any excess solution using an absorbent tissue.[22]

Pediatric patients: The safety and effectiveness of IV phenylephrine in pediatric patients have not been established. 

Older patients: The limited data on phenylephrine's effectiveness in individuals 65 and older warrant careful consideration when selecting doses. Phenylephrine should be initiated at the lower end of the dosage spectrum, considering the potential for age-related hepatic, renal, and cardiac impairment and polypharmacy-related factors.

Adverse Effects

The most frequently reported adverse reactions of phenylephrine comprise nausea, vomiting, headache, and nervousness in patients while awake. Due to its selective alpha-receptor stimulation, phenylephrine can induce baroreceptor-mediated reflex bradycardia. In cases of bradycardia and hypotension, healthcare providers should contemplate various classes of vasopressor medications. In specific patient populations, primarily hypovolemic patients with cardiac dysfunction, phenylephrine has the potential to elevate afterload more than preload, leading to reduced cardiac output and potentially worsening conditions such as angina, heart failure, and pulmonary hypertension.[9]

Drug-Drug Interactions

The medications listed below effectively increase the pressor effect of phenylephrine.

Propranolol: This drug is a nonselective beta-adrenergic antagonist that enhances the vasoconstrictive effects of phenylephrine by inhibiting the influence of sympathetic stimulation on the heart and blood vessels.

Clonidine: This drug is an alpha-2 adrenergic agonist that suppresses sympathetic outflow from the central nervous system, thereby increasing sensitivity to vasoconstrictors such as phenylephrine.

Amitriptyline: This drug is a tricyclic antidepressant that extends the action of endogenous norepinephrine by inhibiting its reuptake, thereby enhancing phenylephrine's effects.

Atomoxetine: This drug is a norepinephrine reuptake inhibitor that increases the availability of norepinephrine, thereby enhancing the pressor effect of phenylephrine.

Prednisone: This drug and other steroids sensitize vasculature to catecholamines, such as phenylephrine, thereby augmenting their vasoconstrictive action.

Ergot alkaloids: These drugs possess vasoconstrictor properties, and when used in conjunction with phenylephrine, they produce additive or synergistic effects on blood pressure.[23]

MAO inhibitors: These inhibitors increase the availability of norepinephrine, thereby potentiating phenylephrine's pressor response.[24]

The medications listed below effectively decrease the pressor effect of phenylephrine.

Phenothiazines, such as chlorpromazine:  Phenothiazines are known for their primary antipsychotic property, and they exhibit alpha-1 adrenergic antagonist activity. This secondary characteristic reduces phenylephrine's pressor effect by obstructing the vasoconstrictive actions mediated through alpha-1 receptors.

Alpha-1 adrenergic antagonists: These antagonists directly inhibit the alpha-1 receptors on smooth muscle, counteracting the vasoconstrictive effects of phenylephrine.[25]

Contraindications

There are no definitive contraindications to phenylephrine except hypersensitivity to the drug or its components.[26] IV phenylephrine contains sodium metabisulfite, which can induce allergic reactions, including anaphylactic symptoms or less severe asthmatic episodes in susceptible individuals.[27] The exact prevalence of sulfite sensitivity remains unclear but is likely low.

Warning and Precautions

• Phenylephrine use warrants caution in patients with a history of bradycardia, severe cardiac dysfunction, and hypovolemia.
• IV phenylephrine may worsen angina, heart failure, or pulmonary arterial hypertension in patients with severe arteriosclerosis or a history of angina.
• Individuals with autonomic dysfunction, possibly resulting from spinal cord injuries, may experience an increased pressure response to adrenergic drugs such as phenylephrine.
• The extravasation of phenylephrine can lead to tissue necrosis or sloughing.[28]
• The concurrent use of sympathomimetic drugs can intensify the pressor effect of phenylephrine, potentially increasing the risk of hemorrhagic stroke.[29]

Monitoring

Currently, no specific protocols exist for monitoring the use of IV phenylephrine. However, vasoactive medications should only be administered within perioperative or ICU settings or in situations where monitoring of heart rate, rhythm, blood pressure, and pulse oximetry is accessible. Although many traditional texts recommend administering all vasoactive medications via a central line, it is common practice to administer phenylephrine peripherally in the operative setting. This approach has been proven safe, even during prolonged infusions through 18- to 20-gauge IV catheters placed in large veins, provided frequent site inspections are conducted.[18] 

Despite the prevalent practice of administering IV phenylephrine peripherally, a systematic review of published articles concerning the peripheral administration of vasoactive medications and reports of extravasation revealed only 2 instances of skin necrosis. These cases occurred in high-risk patients receiving peripherally administered phenylephrine.[30] Administering phenylephrine through central venous catheters, whenever feasible, or the most prominent proximal vein available is recommended. Regular inspections and blood aspiration should be conducted.

Topical, ophthalmic, and nasal administrations of phenylephrine are generally well-tolerated, although there is always a potential concern for systemic absorption. Although there have been reports of hemodynamic instability associated with administering higher concentrations (10%) of ophthalmic phenylephrine, using lesser concentrations (2.5%) has resulted in no statistically significant difference in heart rate or blood pressure.[31] There seems to be no significant impact on hemodynamics when phenylephrine is administered at standard dosages.[19][32][33][34][35]

Toxicity

Currently, there is no known antidote for IV phenylephrine. Hypertension resulting from excessive dosing or an exaggerated response is typically transient, primarily due to the short duration of action. The treatment for hypertension or symptomatic reflex bradycardia involves discontinuing the administration of phenylephrine and administering chronotropic agents or vasodilators as necessary. The treatment for tissue extravasation resulting from peripherally administered phenylephrine primarily involves supportive care, including fluid aspiration, warming, and elevation. In some cases, subcutaneous phentolamine can also be considered.[36]

Enhancing Healthcare Team Outcomes

Phenylephrine is frequently administered in diverse hospital settings, including the ICU, operating room, labor and delivery, and emergency department. The dilution and administration of the medication may necessitate the involvement of multiple healthcare providers, such as pharmacists, nurses, advanced care practitioners, certified registered nurse anesthetists, and physicians.

Manufacturers typically supply IV phenylephrine in highly concentrated 10 mg/mL doses, necessitating dilution before administration. Phenylephrine is often linked to medication errors and can contribute to up to 10% of all errors in the perioperative setting. For this reason, it is crucial for pharmacists and nurses, in particular, to maintain clear communication among patients and healthcare providers to guarantee accurate dosing and administration.

All healthcare providers responsible for administering phenylephrine to patients should acquaint themselves with the correct dilution procedures.[37] According to the manufacturer's guidelines for bolus dosing, 10 mg of phenylephrine should be mixed with 99 mL of 5% dextrose or 0.9% sodium chloride solutions, resulting in a 100 mcg/mL concentration. For continuous infusions, the recommendation is that 10 mg of phenylephrine be added to 500 mL of 5% dextrose or 0.9% sodium chloride solutions, yielding a 20 mcg/mL concentration.

When both pharmacists and nurses are familiar with the correct dosing and dilution of the medication, they can act as a dual safety check alongside the physician to confirm the appropriateness of dosing. Communication channels should allow them to communicate their concerns with the ordering physician promptly.

Notably, the Rapid Response and Code teams are composed of members with varying levels of education and experience, even though they may reduce morbidity and mortality.[38][39] As phenylephrine may be the preferred vasopressor in numerous emergency situations, any potential code team leader should be familiar with and rehearse the direction of its administration. The use of specific closed-loop communications, such as "Please dilute a 10-mg vial of phenylephrine in a 100-mL bag of normal saline and administer 2 mL of 100 mcg/mL through the patient's central line, and inform me when it has been given," as opposed to general instructions, such as "Please give the patient 200 mcg of phenylephrine," has been demonstrated not only to decrease medication errors but also to improve the speed of task completion during emergencies significantly.[40] This information is derived from a prospective observational study with intervention-level II evidence as its foundation.

This study underscores the significance of a collaborative interprofessional team approach in optimizing therapy with phenylephrine and mitigating medication errors. Healthcare professionals, including clinicians, pharmacists, and nurses, should prioritize patient education. Patients should be informed that oral OTC phenylephrine-containing products are not recommended. However, other topical formulations of phenylephrine may be utilized for approved indications.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Kazemi A, McLaren JW, Sit AJ. Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes. Invest Ophthalmol Vis Sci. 2021 Oct 04;62(13):4. [PMC free article: PMC8504193] [PubMed: 34617960]

2.

Margetis N. Pathophysiology of internal hemorrhoids. Ann Gastroenterol. 2019 May-Jun;32(3):264-272. [PMC free article: PMC6479658] [PubMed: 31040623]

3.

Bivalacqua TJ, Allen BK, Brock G, Broderick GA, Kohler TS, Mulhall JP, Oristaglio J, Rahimi LL, Rogers ZR, Terlecki RP, Trost L, Yafi FA, Bennett NE. Acute Ischemic Priapism: An AUA/SMSNA Guideline. J Urol. 2021 Nov;206(5):1114-1121. [PubMed: 34495686]

4.

Tanne JH. Phenylephrine: Commonly used decongestant in cold and flu remedies doesn't work, says FDA. BMJ. 2023 Sep 18;382:2124. [PubMed: 37722752]

5.

Cooper BE. Review and update on inotropes and vasopressors. AACN Adv Crit Care. 2008 Jan-Mar;19(1):5-13; quiz 14-5. [PubMed: 18418098]

6.

Mercier FJ, Augè M, Hoffmann C, Fischer C, Le Gouez A. Maternal hypotension during spinal anesthesia for caesarean delivery. Minerva Anestesiol. 2013 Jan;79(1):62-73. [PubMed: 23135692]

7.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R., Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165-228. [PMC free article: PMC7095153] [PubMed: 23361625]

8.

Yue JK, Tsolinas RE, Burke JF, Deng H, Upadhyayula PS, Robinson CK, Lee YM, Chan AK, Winkler EA, Dhall SS. Vasopressor support in managing acute spinal cord injury: current knowledge. J Neurosurg Sci. 2019 Jun;63(3):308-317. [PubMed: 28252264]

9.

Yamazaki T, Shimada Y, Taenaka N, Oshumi H, Takezawa J, Yoshiya I. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med. 1982 Jul;10(7):432-5. [PubMed: 7083867]

10.

Flancbaum L, Dick M, Dasta J, Sinha R, Choban P. A dose-response study of phenylephrine in critically ill, septic surgical patients. Eur J Clin Pharmacol. 1997;51(6):461-5. [PubMed: 9112060]

11.

Gregory JS, Bonfiglio MF, Dasta JF, Reilley TE, Townsend MC, Flancbaum L. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med. 1991 Nov;19(11):1395-400. [PubMed: 1935160]

12.

Esteve-Taboada JJ, Del Águila-Carrasco AJ, Bernal-Molina P, Ferrer-Blasco T, López-Gil N, Montés-Micó R. Effect of Phenylephrine on the Accommodative System. J Ophthalmol. 2016;2016:7968918. [PMC free article: PMC5174178] [PubMed: 28053778]

13.

Gelotte CK, Parasrampuria DA, Zimmerman BA. Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents. Pulm Ther. 2023 Mar;9(1):139-150. [PMC free article: PMC9931972] [PubMed: 36480111]

14.

Cheng JK, Pan MH, Wu KH, Mok MS, Wei TT. Epidural phenylephrine attenuates hypotension induced by alkalinized lidocaine epidural anesthesia. Anesth Analg. 1999 Jun;88(6):1322-6. [PubMed: 10357338]

15.

Ridyard DG, Phillips EA, Vincent W, Munarriz R. Use of High-Dose Phenylephrine in the Treatment of Ischemic Priapism: Five-Year Experience at a Single Institution. J Sex Med. 2016 Nov;13(11):1704-1707. [PubMed: 27692841]

16.

Lonjaret L, Lairez O, Minville V, Geeraerts T. Optimal perioperative management of arterial blood pressure. Integr Blood Press Control. 2014;7:49-59. [PMC free article: PMC4178624] [PubMed: 25278775]

17.

Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015 May;20(3):249-60. [PubMed: 25432872]

18.

Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015 Sep;10(9):581-5. [PubMed: 26014852]

19.

Gelotte CK, Zimmerman BA. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Clin Drug Investig. 2015 Sep;35(9):547-58. [PMC free article: PMC4559581] [PubMed: 26267590]

20.

Traynor K. FDA advisers want more data about phenylephrine. Am J Health Syst Pharm. 2008 Feb 01;65(3):193-4. [PubMed: 18215998]

21.

Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb;124(2):270-300. [PubMed: 26580836]

22.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 31, 2018. Phenylephrine. [PubMed: 30000498]

23.

Cherewyk JE, Parker SE, Blakley BR, Al-Dissi AN. Sustained vascular contractile response induced by an R- and S-epimer of the ergot alkaloid ergocristine and attenuation by a noncompetitive antagonist. J Anim Sci. 2022 Sep 01;100(9) [PMC free article: PMC9492154] [PubMed: 35775420]

24.

Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, Cornett EM, Kaye AM, Kaye AD. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol Res. 2022;10(4):39576. [PMC free article: PMC9680847] [PubMed: 36425231]

25.

Hillelsohn JH, Liu GT, Hymowitz MB, Shrivastava A, Schultz JS. The differential pupillary response to 2.5% phenylephrine in patients taking tamsulosin. J Ocul Pharmacol Ther. 2015 Apr;31(3):169-73. [PubMed: 25658979]

26.

Vu B, Wong A, Marcus-Freeman S. Allergic Reaction to Phenylephrine. Fed Pract. 2017 Feb;34(2):41-44. [PMC free article: PMC6372024] [PubMed: 30766257]

27.

Vally H, Misso NL. Adverse reactions to the sulphite additives. Gastroenterol Hepatol Bed Bench. 2012 Winter;5(1):16-23. [PMC free article: PMC4017440] [PubMed: 24834193]

28.

Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the Peripheral Administration of Vasopressor Agents. J Intensive Care Med. 2019 Jan;34(1):26-33. [PubMed: 28073314]

29.

Tark BE, Messe SR, Balucani C, Levine SR. Intracerebral hemorrhage associated with oral phenylephrine use: a case report and review of the literature. J Stroke Cerebrovasc Dis. 2014 Oct;23(9):2296-300. [PMC free article: PMC4180794] [PubMed: 25156786]

30.

Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. J Crit Care. 2015 Jun;30(3):653.e9-17. [PubMed: 25669592]

31.

Stavert B, McGuinness MB, Harper CA, Guymer RH, Finger RP. Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2015 Jun;133(6):647-52. [PubMed: 25789577]

32.

Ah-Kee EY, Li Yim JF. Bilateral acute angle closure glaucoma precipitated by over the counter oral decongestant. Int J Ophthalmol. 2014;7(2):387-8. [PMC free article: PMC4003102] [PubMed: 24790890]

33.

Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother. 2007 Mar;41(3):381-90. [PubMed: 17264159]

34.

Bellew SD, Johnson KL, Nichols MD, Kummer T. Effect of Intranasal Vasoconstrictors on Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled Trial. J Emerg Med. 2018 Oct;55(4):455-464. [PMC free article: PMC6202065] [PubMed: 30195946]

35.

Myers MG, Iazzetta JJ. Intranasally administered phenylephrine and blood pressure. Can Med Assoc J. 1982 Sep 01;127(5):365-8. [PMC free article: PMC1862005] [PubMed: 7104913]

36.

Al-Benna S, O'Boyle C, Holley J. Extravasation injuries in adults. ISRN Dermatol. 2013;2013:856541. [PMC free article: PMC3664495] [PubMed: 23738141]

37.

Nanji KC, Patel A, Shaikh S, Seger DL, Bates DW. Evaluation of Perioperative Medication Errors and Adverse Drug Events. Anesthesiology. 2016 Jan;124(1):25-34. [PMC free article: PMC4681677] [PubMed: 26501385]

38.

Rocha HAL, Alcântara ACC, Rocha SGMO, Toscano CM. Effectiveness of rapid response teams in reducing intrahospital cardiac arrests and deaths: a systematic review and meta-analysis. Rev Bras Ter Intensiva. 2018 Jul-Sept;30(3):366-375. [PMC free article: PMC6180469] [PubMed: 30328990]

39.

Buist M, Harrison J, Abaloz E, Van Dyke S. Six year audit of cardiac arrests and medical emergency team calls in an Australian outer metropolitan teaching hospital. BMJ. 2007 Dec 08;335(7631):1210-2. [PMC free article: PMC2128682] [PubMed: 18048504]

40.

El-Shafy IA, Delgado J, Akerman M, Bullaro F, Christopherson NAM, Prince JM. Closed-Loop Communication Improves Task Completion in Pediatric Trauma Resuscitation. J Surg Educ. 2018 Jan-Feb;75(1):58-64. [PubMed: 28780315]

Disclosure: Evan Richards declares no relevant financial relationships with ineligible companies.

Disclosure: Michael Lopez declares no relevant financial relationships with ineligible companies.

Disclosure: Christopher Maani declares no relevant financial relationships with ineligible companies.